Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31622621)

  • 1. Therapeutic Targeting of the Colorectal Tumor Stroma.
    Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
    Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
    Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
    Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
    Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
    Front Immunol; 2018; 9():3107. PubMed ID: 30692993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
    Yu G; Wu Y; Wang W; Xu J; Lv X; Cao X; Wan T
    Cell Mol Immunol; 2019 Apr; 16(4):401-409. PubMed ID: 29622799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?
    Slade DJ
    Trends Cancer; 2021 Mar; 7(3):185-187. PubMed ID: 33309240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
    Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
    Wang Y; Wei B; Gao J; Cai X; Xu L; Zhong H; Wang B; Sun Y; Guo W; Xu Q; Gu Y
    J Immunol; 2020 Nov; 205(10):2905-2915. PubMed ID: 33028620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
    Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
    Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab for the treatment of colorectal cancer.
    Smith KM; Desai J
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.